Transaction DateRecipientSharesTypePriceValue
17th February 2021Alexandria Forbes15,000Open or private sale$15.57$233,550.00
16th February 2021Alexandria Forbes15,000Open or private sale$15.60$234,000.00
15th February 2021Nicole Seligman5,718Exercise of derivative$0.00
15th February 2021Nicole Seligman104Grant/award etc.$0.00
8th February 2021Advisors Llc Perceptive1,250,000Open or private purchase$16.00$20,000,000.00
8th February 2021Advisors Llc Perceptive1,770,600Conversion of derivative$0.00
8th February 2021Advisors Llc Perceptive2,941,769Conversion of derivative$0.00
8th February 2021Advisors Llc Perceptive2,857,795Conversion of derivative$0.00
28th January 2021Advisors Llc Perceptive4,219,409Open or private purchase$2.37$9,999,999.33
25th January 2021Advisors Llc Perceptive311,111Open or private purchase$22.50$6,999,997.50
Meira G Tx Holdings Plc
Meira G Tx Holdings Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


MeiraGTx Holdings Plc is a clinical-stage biotech company. It engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.


Ticker: MGTX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1735438
Employees: 157
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $195 M (-14%)
Other Assets, Current: $2 M (-5%)
Assets, Current: $235 M (-12%)
Property, Plant and Equipment, Net: $28 M (16%)
Other Assets, Noncurrent: $194 Th (0%)
Assets: $291 M (-10%)
Accounts Payable, Current: $3 M (-17%)
Accrued Liabilities, Current: $18 M (0%)
Liabilities, Current: $47 M (-5%)
Liabilities: $118 M (-11%)
Common Stock, Value, Issued: $1 Th (1%)
Common Stock, Shares, Issued: $37 M (1%)
Retained Earnings (Accumulated Deficit): $244 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $3 M (48%)
Stockholders' Equity (Parent): $173 M (0%)
Liabilities and Equity: $291 M (-10%)
Revenue: $2 M (-62%)
Research and Development: $16 M (-33%)
General and Administrative Expenses: $11 M (-50%)
Operating Income/Loss: $25 M (-38%)
Provision for income taxes: $91 Th (0%)